Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Arena Pharmaceuticals prepares novel GPR119 receptor agonists

May 7, 2013

Merck & Co. gains FDA approval for Liptruzet combination tablet

May 6, 2013

DiaMedica begins first-in-human trial of DM-199

May 3, 2013

FDA approves Raptor Pharmaceutical's treatment for nephropathic cystinosis

May 3, 2013

Trimel Pharmaceuticals submits NDA to FDA for CompleoTRT

May 2, 2013

Transition Therapeutics reports data from proof-of-concept study of TT-401

May 2, 2013

In vivo results described for novel enzyme replacement therapy for Pompe disease

May 2, 2013

Novartis presents new dual function fusion proteins for diabetes

May 2, 2013

Merck & Co. and Pfizer to develop and commercialize ertugliflozin

April 30, 2013

EMA's CHMP recommends restricting use of Protelos/Osseor

April 29, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...